| Positive Rankings |
Estimated Revenue Growth
Cara Therapeutics Inc. rank is 88 |
Debt-to-Equity
Cara Therapeutics Inc. rank is 208 |
90 Day Gain
Cara Therapeutics Inc. rank is 296 |
Target Prices
The average analysts' target price is $26.00 for Cara Therapeutics Inc. using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Cara Therapeutics Inc. is ranked 302. |
10 Day Gain
Cara Therapeutics Inc. rank is 333 |
Highest Cash Growth
Cara Therapeutics Inc. rank is 345 |
Low vPut/Call
Cara Therapeutics Inc. has a low Put/Call ratio of 0.33 on active options expiring within the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Cara Therapeutics Inc. is ranked 640. |
Low Put/Call
Cara Therapeutics Inc. has a low Put/Call ratio of 0.59 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Cara Therapeutics Inc. is ranked 1273. |
| Negative Rankings |
High/Dropping MACD
The MACD remains positive, but is dropping... suggesting a possible near-term correction. Of companies with a positive, but declining MACD, Cara Therapeutics Inc. is ranked 135. |
Overbought RSI
The 14 Day Relative-Strength Index for Cara Therapeutics Inc. is 70.2. An RSI above 70 indicates the stock is overbought. Among companies with a high RSI, Cara Therapeutics Inc. is ranked 214. |
Down EPS Surprise
Cara Therapeutics Inc. missed the consensus earnings estimate when it last reported quarterly earnings. |
Negative ROA
Cara Therapeutics Inc. rank is 440 |
Negative ROE
Cara Therapeutics Inc. rank is 473 |
Price-to-Book
Cara Therapeutics Inc. rank is 574 |
Negative Revenue Growth
Cara Therapeutics Inc. rank is 681 |
Overbought Stochastics
Cara Therapeutics Inc. rank is 823 |
